PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light HollandVANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that it has entered into a consulting relationship with Red Light Holland Corp. (“Red Light”), (CSE: TRIP) to consult
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Huxley Health Inc. (“Huxley” or the “Company”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that have shaped Huxley over the past year. Key Highlights: Acquisition of Sintalica Corp: Huxley strengthens its position in psychedelics-based treatments for Neuroinflammatory Disorders through the successful acquisition of Sintalica Corp.New Leadership: High profile additions creating a d